PPH · NASDAQ · ETF
VanEck Pharmaceutical ETF (PPH) Price, Holdings & Fees
VanEck Pharmaceutical ETF (PPH) closed at $523.56 on Oct 9, 2026, down 1.24% from the previous close of $530.11.
Share price, past year
1Y −13.25%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $523.56 |
| Sep 30, 2026 | $543.23 |
| Aug 31, 2026 | $512.04 |
| Jul 31, 2026 | $538.40 |
| Jun 30, 2026 | $546.45 |
| May 29, 2026 | $569.64 |
| Apr 30, 2026 | $572.63 |
| Mar 31, 2026 | $602.45 |
| Feb 27, 2026 | $606.00 |
| Jan 30, 2026 | $640.39 |
| Dec 31, 2025 | $635.94 |
| Nov 28, 2025 | $599.40 |
| Oct 31, 2025 | $606.33 |
Key statistics
- Expense ratio
- 0.36%
- as of Jan 31, 2026
- Net assets
- $879.5M
- as of Jun 30, 2026
- Holdings
- 26
- as of Jun 30, 2026
- 52-week range
- $512.04 – $657.21
VanEck Pharmaceutical ETF's expense ratio is 0.36%: $36.00 a year on $10,000 invested.
Holdings
VanEck Pharmaceutical ETF held 26 investments worth $879.46M as of Jun 30, 2026. Its largest holding was Eli Lilly & Co, at 20.23% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | Eli Lilly & Co | 20.23% | $177.92M |
| 2 | Novartis AG | 10.63% | $93.44M |
| 3 | Merck & Co Inc | 9.85% | $86.58M |
| 4 | Novo Nordisk A/S | 5.37% | $47.19M |
| 5 | AbbVie Inc | 4.57% | $40.23M |
| 6 | Pfizer Inc | 4.51% | $39.64M |
| 7 | Bristol-Myers Squibb Co | 4.47% | $39.30M |
| 8 | GSK PLC | 4.42% | $38.85M |
| 9 | Johnson & Johnson | 4.35% | $38.30M |
| 10 | AstraZeneca PLC | 4.33% | $38.11M |
| 11 | McKesson Corp | 4.12% | $36.25M |
| 12 | Sanofi SA | 4.00% | $35.21M |
| 13 | Cencora Inc | 3.36% | $29.51M |
| 14 | Haleon PLC | 3.09% | $27.18M |
| 15 | Teva Pharmaceutical Industries Ltd | 3.06% | $26.89M |
| 16 | Takeda Pharmaceutical Co Ltd | 2.87% | $25.26M |
| 17 | Zoetis Inc | 2.10% | $18.46M |
| 18 | Viatris Inc | 1.10% | $9.63M |
| 19 | Jazz Pharmaceuticals PLC | 1.08% | $9.50M |
| 20 | Axsome Therapeutics Inc | 0.77% | $6.75M |
| 21 | Corcept Therapeutics Inc | 0.50% | $4.43M |
| 22 | Elanco Animal Health Inc | 0.35% | $3.11M |
| 23 | State Street Global Advisors | 0.28% | $2.43M |
| 24 | Organon & Co | 0.23% | $2.01M |
| 25 | Bausch Health Cos Inc | 0.10% | $860.86K |
Top 25 of 26 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 99.51% |
| Cash and short-term investments | 0.28% |
| Country | % of fund |
|---|---|
| United States | 60.78% |
| United Kingdom | 11.84% |
| Switzerland | 10.63% |
| Denmark | 5.37% |
| France | 4.00% |
| Israel | 3.06% |
| Japan | 2.87% |
| Ireland | 1.14% |
| Canada | 0.10% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jun 30, 2026, VanEck Pharmaceutical ETF's total return was +5.83%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jun 30, 2026 | +4.42% |
| May 31, 2026 | +2.86% |
| Apr 30, 2026 | −1.47% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- VanEck Pharmaceutical ETF
- Ticker
- PPH
- Exchange
- NASDAQ
- Fund type
- ETF
- Trust
- VanEck ETF Trust
- SEC series ID
- S000034409
- SEC CIK
- 0001137360
- Fractional shares
- Yes
Recent SEC filings
- Aug 26, 2026
- 485BPOSProspectus updateSep 23, 2026
- 485BPOSProspectus updateSep 15, 2026
- Sep 4, 2026
- 485BPOSProspectus updateAug 27, 2026
- 485BPOSProspectus updateAug 18, 2026
- Jul 8, 2026
- 485BPOSProspectus updateJun 22, 2026
Shareholder reports and prospectuses are filed by VanEck ETF Trust, the trust behind VanEck Pharmaceutical ETF, and cover all of its funds.
Frequently asked questions
What is PPH's price?
VanEck Pharmaceutical ETF (PPH) closed at $523.56 on Oct 9, 2026, down 1.24% from the previous close of $530.11.
What is PPH's expense ratio?
VanEck Pharmaceutical ETF's expense ratio is 0.36%: $36.00 a year on $10,000 invested.
What does PPH hold?
VanEck Pharmaceutical ETF held 26 investments worth $879.46M as of Jun 30, 2026. Its largest holding was Eli Lilly & Co, at 20.23% of the fund. Its five largest holdings were Eli Lilly & Co, Novartis AG, Merck & Co Inc, Novo Nordisk A/S, AbbVie Inc.
How has PPH performed?
Over the 3 months to Jun 30, 2026, VanEck Pharmaceutical ETF's total return was +5.83%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 26, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jan 31, 2026. Prices are generated sample data for development. Data sources and disclosures